Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Sub Type
Sequence Type COMPLETE
Record UNII
1PE72K8X46
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
MU-TYPE OPIOID RECEPTOR
Common Name
English  
MU OPIOID RECEPTOR
Common Name
English  
MU OPIATE RECEPTOR
Common Name
English  
MOR1
Common Name
English  
MOR-1
Common Name
English  
MOP
Common Name
English  
M-OR-1
Common Name
English  
HMOP
Common Name
English  
Code System Code Type Description Access References
FDA UNII
1PE72K8X46
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
PRIMARY
UNIPROT
P35372
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
PRIMARY
From To
1_142 1_219
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_9
N 1_12
N 1_33
N 1_40
N 1_48
Related Record Type Details Access References
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Reported to have 13X the potency of morphine
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
An opioid analgesic drug from the thiambutene family, which has around the same potency as morphine.
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
ANTAGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
AGONIST
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 2.5
IC50
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Blood furanylfentanyl concentrations are expected to be in a range of 1-45 ?g/L in victims of fatal overdosage.[
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
AGONIST
HUMAN RECEPTOR
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
PARTIAL AGONIST->TARGET
Mediator Substance Details
none
BINDING
PARTIAL AGONIST
Ki
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
COMPETITIVE INHIBITOR
(+)-isomer
Ki
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Cannot cross blood-brain barrier due to positive charge
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Herkinorin is a ?-opioid agonist with more than 100x higher ?-opioid affinity and 50x lower ?-opioid affinity compared to Salvinorin A.
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
BINDING
Mu Receptor [3H]DAMGO BINDING INHIBITION
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to ?-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in ?-opioid binding.
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
ANTAGONIST
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
ED50(mg/kg) = 0.220, Potency ratio to morphine = 1.5, Potency ratio to fentanyl = 0.03
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
PARTIAL AGONIST
TRV0109662 is a weak (EC50= 5 mcM) partial agonist of the human mu-opioid receptor.
EC50
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
AGONIST
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 4.0
IC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:16 EDT 2021 , Edited by admin on Wed Aug 04 03:04:16 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BIOASSAY (CELLULAR)
Emax 180 of hydromorphone
EC50
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
AGONIST
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 2.1
IC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
EC50
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:15 EDT 2021 , Edited by admin on Wed Aug 04 03:04:15 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:04:14 EDT 2021 , Edited by admin on Wed Aug 04 03:04:14 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
AMINO ACID SUBSTITUTION [1_365] [1_377] DEXFOSFOSERINE VI4F0K069V
AMINO ACID SUBSTITUTION [1_372] THREONINE PHOSPHATE 3L4WX7B1EI
AMINO ACID SUBSTITUTION [1_168] TYROSINE O-PHOSPHATE 2R86C98KDX
Name Property Type Amount Referenced Substance Defining Parameters Access References
MOL_WEIGHT CHEMICAL
0
Created Wed Aug 04 03:04:13 EDT 2021
Created By admin
Last Edited Wed Aug 04 03:04:13 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
2 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
3 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62055 NCI THESAURUS
4 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
5 PUBCHEM PUBCHEM NOMEN PUBLIC_DOMAIN_RELEASE
6 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
7 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
8 https://en.wikipedia.org/wiki/4-Methylphenethylacetylfentanyl WIKI NOMEN PUBLIC_DOMAIN_RELEASE
9 https://en.wikipedia.org/wiki/Herkinorin WIKI PUBLIC_DOMAIN_RELEASE
10 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm CFR
11 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
12 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
13 https://www.drugbank.ca/drugs/DB06274 WEBSITE PUBLIC_DOMAIN_RELEASE
14 Huttunen, Kristiina M., Hannu Raunio, and Jarkko Rautio. "Prodrugs—from serendipity to rational design." Pharmacological reviews 63.3 (2011): 750-771. JA
15 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
16 4-Chloroisobutyrylfentanyl WIKI PUBLIC_DOMAIN_RELEASE
17 FORENSIC TOXICOL (2008) 26: 1, 1-5 JOURNAL ARTICLE NOMEN
18 Naunyn-Schmiedeberg’s Arch Pharmacol (2000) 362: 116–121 JA
19 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
20 Raynor, Karen, et al. "Characterization of the cloned human mu opioid receptor." Journal of Pharmacology and Experimental Therapeutics 272.1 (1995): 423-428. JA
21 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
22 https://en.wikipedia.org/wiki/Bucinnazine WIKI
23 https://en.wikipedia.org/wiki/Dihydromorphine WIKI PUBLIC_DOMAIN_RELEASE
24 https://en.wikipedia.org/wiki/Heroin WIKI NOMEN PUBLIC_DOMAIN_RELEASE
25 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
26 STN STN (SCIFINDER) NOMEN PUBLIC_DOMAIN_RELEASE
27 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
28 Generated from relationship on:'BUPRENORPHINE' SYSTEM
29 https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
30 Lobbezoo, Marinus W., Willem Soudijn, and Ineke Van Wijngaarden. "Opiate receptor interaction of compounds derived from or structurally related to fentanyl." Journal of medicinal chemistry 24.7 (1981): 777-782. JA PUBLIC_DOMAIN_RELEASE
31 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
32 4-Chloroisobutyrylfentanyl WIKI PUBLIC_DOMAIN_RELEASE
33 https://en.wikipedia.org/wiki/3-Phenylpropanoylfentanyl WIKI NOMEN PUBLIC_DOMAIN_RELEASE
34 Lobbezoo, Marinus W., Willem Soudijn, and Ineke Van Wijngaarden. "Opiate receptor interaction of compounds derived from or structurally related to fentanyl." Journal of medicinal chemistry 24.7 (1981): 777-782. JA PUBLIC_DOMAIN_RELEASE
35 Helander, A., M. Bäckberg, and O. Beck. "MT-45, a new psychoactive substance associated with hearing loss and unconsciousness." Clinical toxicology 52.8 (2014): 901-904. JOURNAL ARTICLE NOMEN
36 P122 INN PUBLIC_DOMAIN_RELEASE
37 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:35:46 EDT 2017
38 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI PUBLIC_DOMAIN_RELEASE NOMEN
39 Orthofluorofentanyl WIKI
40 Tetrahydrofuranylfentanyl WIKI PUBLIC_DOMAIN_RELEASE
41 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C494 NCI THESAURUS
42 Report on a novel emerging class of highly potent benzimidazole NPS opioids: Peter Blanckaert Annelies Cannaert Blanckaert, Peter; Cannaert, Annelies; Uytfanghe, Katleen Van; Hulpia, Fabian; Deconinck, Eric; Calenbergh, Serge Van; Stove, Christophe. "Report on a novel emerging class of highly potent benzimidazole NPS opioids:". Drug Testing and Analysis. n/a (n/a). doi:10.1002/dta.2738. ISSN 1942-7611 JA
43 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
44 Report on a novel emerging class of highly potent benzimidazole NPS opioids: Peter Blanckaert Annelies Cannaert Blanckaert, Peter; Cannaert, Annelies; Uytfanghe, Katleen Van; Hulpia, Fabian; Deconinck, Eric; Calenbergh, Serge Van; Stove, Christophe. "Report on a novel emerging class of highly potent benzimidazole NPS opioids:". Drug Testing and Analysis. n/a (n/a). doi:10.1002/dta.2738. ISSN 1942-7611 JA
45 Lobbezoo, Marinus W., Willem Soudijn, and Ineke Van Wijngaarden. "Opiate receptor interaction of compounds derived from or structurally related to fentanyl." Journal of medicinal chemistry 24.7 (1981): 777-782. JA PUBLIC_DOMAIN_RELEASE
46 https://en.wikipedia.org/wiki/Parafluorofentanyl WIKI
47 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
48 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 03:04:13 EDT 2021
49 https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
50 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
51 https://en.wikipedia.org/wiki/Clonitazene WIKI
52 NFLIS-DRUG List (Date 9/25/2018) WEBSITE PUBLIC_DOMAIN_RELEASE
53 Wang, Jun-Sheng, and C. Lindsay DeVane. "Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro." Drug Metabolism and Disposition 31.6 (2003): 742-747. JA PUBLIC_DOMAIN_RELEASE
54 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
55 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
56 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
57 Fossler, Michael J., et al. "Oliceridine, a Novel G Protein–Biased Ligand at the ??Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model." The Journal of Clinical Pharmacology 58.6 (2018): 762-770. JA PUBLIC_DOMAIN_RELEASE
58 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
59 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
60 Armenian, Patil, et al. "Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review." Neuropharmacology 134 (2018): 121-132. JA POT
61 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
62 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
63 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
64 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
65 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
66 Electronic Code of Federal Regulations e-CFR data is current as of June 21, 2019 CFR PUBLIC_DOMAIN_RELEASE
67 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
68 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
69 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI NOMEN PUBLIC_DOMAIN_RELEASE
70 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
71 https://en.wikipedia.org/wiki/Bucinnazine WIKI
72 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI PUBLIC_DOMAIN_RELEASE
73 Tetrahydrofuranylfentanyl WIKI PUBLIC_DOMAIN_RELEASE
74 ITI 333 WEB PAGE
75 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C494 NCI THESAURUS
76 https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=3154 WEB PAGE
77 https://en.wikipedia.org/wiki/Piperidylthiambutene WIKI
78 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
79 Mohr, Amanda LA, et al. "Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in postmortem casework." Journal of Analytical Toxicology 40.9 (2016): 709-717. JA
80 https://en.wikipedia.org/wiki/Bevenopran WIKI
81 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
82 Phenaridine WIKI
83 Cyclopropylfentanyl WIKI
84 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
85 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
86 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
87 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
88 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
89 Leander, J. D. "Buprenorphine has potent kappa opioid receptor antagonist activity." Neuropharmacology 26.9 (1987): 1445-1447. JA
90 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
91 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
92 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
93 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
94 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
95 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI NOMEN PUBLIC_DOMAIN_RELEASE
96 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
97 Lobbezoo, Marinus W., Willem Soudijn, and Ineke Van Wijngaarden. "Opiate receptor interaction of compounds derived from or structurally related to fentanyl." Journal of medicinal chemistry 24.7 (1981): 777-782. JA PUBLIC_DOMAIN_RELEASE
98 https://en.wikipedia.org/wiki/NFEPP WIKI
99 Lobbezoo, Marinus W., Willem Soudijn, and Ineke Van Wijngaarden. "Opiate receptor interaction of compounds derived from or structurally related to fentanyl." Journal of medicinal chemistry 24.7 (1981): 777-782. JA PUBLIC_DOMAIN_RELEASE
100 http://www.uniprot.org/uniprot/P35372 SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
101 Cyclopropylfentanyl WIKI
102 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
103 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
104 Electronic Code of Federal Regulations e-CFR data is current as of June 21, 2019 CFR PUBLIC_DOMAIN_RELEASE
105 Hassanien, Sherif H., et al. "In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis." Drug testing and analysis 12.8 (2020): 1212-1221. JA PUBLIC_DOMAIN_RELEASE
106 Grond, Stefan, and Armin Sablotzki. "Clinical pharmacology of tramadol." Clinical pharmacokinetics 43.13 (2004): 879-923. JA
107 Fossler, Michael J., et al. "Oliceridine, a Novel G Protein–Biased Ligand at the ??Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model." The Journal of Clinical Pharmacology 58.6 (2018): 762-770. JA PUBLIC_DOMAIN_RELEASE
108 https://en.wikipedia.org/wiki/Parafluorofentanyl WIKI
109 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI NOMEN PUBLIC_DOMAIN_RELEASE
110 https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm WEB PAGE
111 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI NOMEN PUBLIC_DOMAIN_RELEASE
112 Prozialeck, Walter C., Jateen K. Jivan, and Shridhar V. Andurkar. "Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects." The Journal of the American Osteopathic Association 112.12 (2012): 792-799. JA
113 https://en.wikipedia.org/wiki/2,2%27-Difluorofentanyl WIKI
114 Huttunen, Kristiina M., Hannu Raunio, and Jarkko Rautio. "Prodrugs—from serendipity to rational design." Pharmacological reviews 63.3 (2011): 750-771. JA
115 UNIPROT UNIPROT NOMEN
116 https://en.wikipedia.org/wiki/List_of_fentanyl_analogues WIKI NOMEN PUBLIC_DOMAIN_RELEASE
117 USP/NF SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
118 Prozialeck, Walter C., Jateen K. Jivan, and Shridhar V. Andurkar. "Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects." The Journal of the American Osteopathic Association 112.12 (2012): 792-799. JA
119 https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/23.4.280 SRS NOMEN PUBLIC_DOMAIN_RELEASE